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Vancomycin, a branched tricyclic glycosylated peptide antibiotic, is a last-line defence against serious 
infections caused by staphylococci, enterococci and other Gram-positive bacteria. Orally-administered 
vancomycin is the drug of choice to treat pseudomembranous enterocolitis in the gastrointestinal 
tract. However, the risk of vancomycin-resistant enterococcal infection or colonization is significantly 
associated with oral vancomycin. Using the powerful matrix-free assay of co-sedimentation analytical 
ultracentrifugation, reinforced by dynamic light scattering and environmental scanning electron 
microscopy, and with porcine mucin as the model mucin system, this is the first study to demonstrate 
strong interactions between vancomycin and gastric and intestinal mucins, resulting in very large 
aggregates and depletion of macromolecular mucin and occurring at concentrations relevant to oral 
dosing. In the case of another mucin which has a much lower degree of glycosylation (~60%) – bovine 
submaxillary mucin - a weaker but still demonstrable interaction is observed. Our demonstration - for 
the first time - of complexation/depletion interactions for model mucin systems with vancomycin 
provides the basis for further study on the implications of complexation on glycopeptide transit in 
humans, antibiotic bioavailability for target inhibition, in situ generation of resistance and future 
development strategies for absorption of the antibiotic across the mucus barrier.
Vancomycin is a branched tricyclic glycosylated peptide antibiotic. In the clinic, it represents a last-line defence 
against infections caused by Gram-positive pathogenic bacteria. Isolated in 1956 and introduced into clinical 
practice in 1958, it acts by inhibiting cell wall synthesis in sensitive bacteria1. The largely hydrophilic mole-
cule (see Fig. 1a) is able to form hydrogen bond interactions with the terminal d-alanyl-d-alanine moieties of 
the muramyl pentapeptide of the peptidoglycan. Under normal environments, the binding of vancomycin to 
d-Ala-d-Ala inhibits transglycosylase and transpeptidase activities during peptidoglycan growth, preventing the 
incorporation of new peptidoglycan into the expanding matrix, thereby leading to osmotic shock and cell lysis2,3.
Vancomycin was recently the subject of a detailed study using molecular hydrodynamics4. It was shown 
to form dimers (in common with other studies) and the reversibility and strength of the dimerization process 
in four different aqueous solvents (including a medically-used formulation) were studied using short-column 
sedimentation equilibrium in the analytical ultracentrifuge and model-independent SEDFIT-MSTAR analysis 
across a range of loading concentrations. The change in the weight average molar mass Mw with loading concen-
tration was consistent with a monomer-dimer equilibrium. Overlap of data sets of point weight average molar 
masses Mw(r) versus local concentration c(r) for different loading concentrations demonstrated a completely 
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reversible equilibrium process. At the clinical infusion concentration of 5 mg/mL all glycopeptide was dimerized 
whilst at 19 µg/mL (a clinical target trough serum concentration), vancomycin was mainly monomeric ( < 20% 
dimerized)4.
Analysis of the variation of Mw with loading concentration revealed dissociation constants in the range 
25–75 µM, commensurate with a relatively weak association. That study4, alongside companion studies6,7, also 
demonstrated a weak interaction with the A-type bacterial VanS histidine protein kinase involved in the activa-
tion of vancomycin resistance, at least in aqueous solution.
Despite its efficacy, vancomycin comes with potentially toxic side effects8–11, whether the antibiotic is adminis-
tered intravenously or orally. The more intensive dosing regimens recommended by recent guidelines for intrave-
nous vancomycin are associated with increasing reports of nephrotoxicity12; indeed, there is a long-standing, yet 
highly debated, association between vancomycin administration and nephrotoxicity13,14. Rare effects on hearing 
loss have also been reported15,16 through use of high peak serum concentrations of 49.2 µg/mL vancomycin17. 
Studies in recent years have rekindled interest in the best way to administer the antibiotic in the clinic to obtain 
the efficacious concentrations required to combat infections and yet minimise any toxic effects on patients13,14. 
To achieve this, many studies advocate a need to monitor serum concentrations of vancomycin with time18–20 and 
some suggest adjustment of loading doses (standardly 15 mg/kg, or 25–30 mg/kg also administered orally in the 
initial stages of therapy) according to patient disease state and body weight20,21, so that doses are individualised22–24. 
In general, in order to treat serious methicillin-resistant Staphylococcus aureus (MRSA) infections, the aim is to 
maintain vancomycin serum trough concentrations at 15–20 µg/mL18,25,26.
Vancomycin is also administered orally (typically at doses of 500 mg to 2 mg per day in 3-4 divided doses 
and resulting in stool concentrations of 1.4 mg/mL (ranging 0.5–2.0 mg/mL)27. It is used to treat pseudomem-
branous enterocolitis (PE), a disorder primarily caused by Clostridium difficile and occasionally by S. aureus13,28. 
Vancomycin is effective against both of these Gram-positive pathogens and is poorly absorbed from the gastroin-
testinal (GI) tract, thus making vancomycin the drug of choice for treatment of pseudomembranous enterocolitis 
(PE)27. However, orally-administered (and to a lesser extent intravenously-administered) vancomycin, results 
in development of vancomycin-resistant enterococci (VRE)29,30. The risk for VRE infection or colonization is 
significantly associated with oral vancomycin use31–34. It is possible that a component of the gastrointestinal tract 
contributes to selection of VRE through binding of vancomycin within the GI tract resulting in prolonged expo-
sure periods for gut resident microorganisms such as the enterococci to acquire/ or express resistance. If delayed 
transit was the case, it is also noteworthy that vancomycin has significant and sometimes long-lasting inhibitory 
effects on the intestinal microbiota that is reported to be correlated with increased weight gain, asthma and dia-
betes in humans9,35,36.
Because of their protective function in the gastrointestinal tract, their exposed location for potential vancomy-
cin interactions and their ability to provide a formidable permeability barrier with extensive binding properties, 
we investigate using model mucin systems whether gastrointestinal mucins are able to interact with vancomy-
cin (a hydrophilic molecule that is weakly positively-charged at physiological pH). Any interactions could help 
explain the poor absorption of the antibiotic from the intestine and the glycopeptide impacts on the intestinal 
microbiota described above. The investigation involves the application of the powerful molecular hydrodynamic 
assay of co-sedimentation in the analytical ultracentrifuge to analyse interactions between different types of 
mucins and vancomycin. High rotor speeds (~45000 rpm, 130 000 g) are employed to sediment mucin (Fig. 1b) in 
Figure 1. (a) Vancomycin structure (reproduced from Phillips-Jones et al.4 with permission from Nature 
Journals). The structure consists of a heptapeptide with an O-linked disaccharide. Molecular weight = 1449 g/
mol. (b) Mucin structure. Based on a linear random coil model for colonic mucin (see ref. 5). Heavily 
glycosylated regions alternate with regions of low glycosylation, linked every 3-4 residues by disulphide bonds. 
The shadowed area shows the “effective” overall spheroidal volume of influence of this glycoprotein. The degree 
of glycosylation for most mucins of mammalian origin is ~80% although for submaxillary mucins it is lower 
(~60%). Molecular weights can be from 500,000–50 × 106 g/mol depending on the source.
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solution while low rotor speeds (~3000 rpm) are used to sediment large supramolecular complexes of molecular 
weight > 108Da. Our investigation reported here unequivocally demonstrates mucin-vancomycin interactions. 
We reinforce this demonstration of mucin complexation with dynamic (quasi-elastic) light scattering (DLS) 
measurements, a technique which is more sensitive to larger particles, and with environmental scanning electron 
microscopy.
Model mucin systems. Due to the difficulty in obtaining reproducible mucins from the gastrointestinal tract 
in sufficient quantity from human sources37,38 we follow the commonly accepted practice of using pig gastroin-
testinal mucins as our model mucin systems, both pig gastric mucin (PGM) and pig intestinal mucin (PIM)39–43. 
These appear to be the closest of the animal models to the gastrointestinal mucins for humans39,44. Although 
orally administered vancomycin is delivered through gelatin or other coated capsules – and hence with limited 
exposure to the mouth - another model mucin, bovine submaxillary mucin (BSM) is also considered because of 
its relatively low sugar content compared to the gastric and small intestinal mucins. The extension of our findings 
from these model mucins from animals to the case for humans is also considered.
Results
Three concentrations of vancomycin were used in the present study. The rationale for choosing these is based 
on our previous findings4: at 0.125 mg/mL vancomycin is expected to be mostly monomeric, at 1.25 mg/mL (the 
typical concentration found in stools of patients given oral vancomycin) it is approximately 50% dimerized and at 
12.5 mg/mL it is mostly dimeric. Concentrations of mucin were chosen to be low enough to be in the dilute region 
(non-molecular overlap): 0.5 mg/ml for PGM and PIM and 1.0 mg/ml for the smaller BSM.
Analytical Ultracentrifugation (AUC) of solutions of pig gastric mucin (PGM) with vancomycin. 
The 45000 rpm plot (Fig. 2a), shows the 0.5 mg/mL pig gastric mucin control (no vancomycin added) showing 
two components with the main macromolecular mucin component of s values between 5 and 23 S and what hap-
pens to this as the vancomycin concentration is increased to 12.5 mg/mL. The amount of this component dimin-
ishes dramatically through complexation as the vancomycin concentration is increased. The 1.25 and 12.5 mg/
mL additions indicate complete interaction of the mucin but this would be expected as the PGM concentration 
is much lower than the concentration of vancomycin. At 3000 rpm (Fig. 2b), the reverse is seen as the addition of 
vancomycin has produced large aggregates, (~1500 S), increasing as the vancomycin concentration is increased, 
leaving little macromolecular mucin behind as the vancomycin concentration is progressively raised. The extent 
of the depletion of mucin is given in Table 1.
Figure 2. Sedimentation coefficient distribution of pig gastric mucin (PGM)/ vancomycin mixtures at different 
mixing ratio (a) at 45000 rpm (b) at 3000 rpm. 0.5 mg/mL PGM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark 
green), +12.5 mg/mL (red) vancomycin. The 0.5 mg/mL PGM control is shown in black. The dashed lines 




Proportion of mucin lost (%) 
Vancomycin added (mg/ml)
0 0.125 1.25 12.5
PGM 80a 0 38 99 100
PIM 77b 0 23 100 100
BSM 60c 0 0 14 53
Table 1. Proportion (%) of mucin lost (AUC) through complexation as a function of vancomycin added. Rotor 
speed 45000 rpm (130 000 g), 20.0 °C. aSchömig et al.45; bMantle & Allen46; cTsuiki et al.47.
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AUC of solutions of pig intestinal mucin (PIM) with vancomycin. At 0.5 mg/mL and 45000 rpm, 
the PIM control is seen with broad sedimentation coefficient distribution values of up to ~250 S. As with PGM, 
there is a progressive lowering in PIM concentration upon addition of increasing concentrations of vancomycin. 
At 0.125 mg/mL there is a small decrease while at 1.25 mg/mL and at 12.5 mg/mL the PIM disappears altogether, 
indicating complete interaction (Fig. 3). In common with observations with PGM, because of the lower mucin 
concentration relative to vancomycin, the excess vancomycin at 1.25 and 12.5 mg/mL concentrations is observed 
at very low sedimentation coefficient ( < 0.5 S). At 3000 rpm no trace is observed, and this is presumed to be due 
to the fast sedimentation of large vancomycin-mucin aggregates even at lower speed.
AUC of solutions of bovine submaxillary mucin (BSM) with vancomycin. Figure 4 shows the sedi-
mentation coefficient distributions of the interaction of vancomycin with 1 mg/mL bovine submaxillary mucin of 
another model mucin, chosen because of its lower carbohydrate content (Table 1). Although there is a progressive 
loss of mucin concentration with the addition of vancomycin, the effects of the interaction were negligible at 0.125 
and 1.25 mg/mL, respectively, as compared to pig gastric and intestinal mucins. There is however a significant loss 
in mucin concentration in the presence of 12.5 mg/mL vancomycin (Table 1). As with the previous experiments, 
the 1.25 and 12.5 mg/mL peaks at ~0.5 S represent changes in the presence of excess vancomycin.
Dynamic Light Scattering (DLS). Further evidence of mucin-vancomycin complexation was sought using 
DLS and a Malvern Nanosizer-S instrument. The quasi-elastic or “dynamic” light scattering (DLS) data presented 
in Fig. 5 are shown in terms of Provencher (1992)48 - type of analysis of the distribution of apparent translational 
diffusion coefficients transformed via the Stokes-Einstein relation (Eq. 2) into apparent size (equivalent apparent 
hydrodynamic diameter). We use the “volume distribution” method. In a previous study by Malvern instru-
ments49 the intensity, volume and number weighted distributions for a mixture of 60 and 200 nm latex spheres 
with a mass composition of 70% and 30% were compared: it was found the volume method gave an accurate 
reproduction of both the smaller and larger components, and much better than the other procedures so we fol-
low that procedure here. However, values are apparent values as they are obtained at a fixed angle of 173° and we 
have followed the common practice of assuming overall particle sphericity (i.e. no contribution from possible 
rotational or other anisotropic effects). Although not as resolving50, and within the assumptions we have made, 
these results appear to confirm those from the analytical ultracentrifuge by showing the increased presence of 
large supramolecular complexes and depletion of the macromolecular mucin component upon addition of the 
vancomycin, particularly for the stomach and intestinal mucins which have a larger carbohydrate component: 
BSM, with lower glycosylation shows an interaction with lower depletion of the macromolecular mucin.
Figure 3. Sedimentation coefficient distribution of pig intestinal mucin (PIM) and vancomycin at differing 
mixing ratios. Rotor speed 45000 rpm. 0.5 mg/mL PIM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark green), 
+12.5 mg/mL (red) vancomycin. The 0.5 mg/mL PIM control is shown in black.
Figure 4. Sedimentation coefficient distribution of bovine submaxillary mucin (BSM) and vancomycin at 
differing mixing ratio. Rotor speed 45000 rpm. 1.0 mg/mL BSM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark 
green), +12.5 mg/mL (red) vancomycin. The 1.0 mg/mL BSM control is shown in black.
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imaging of mucin-vancomycin complexes using environmental scanning electron microscopy 
(ESEM). Electron microscopy and other imaging methods have been successfully applied in the past to inves-
tigate mucins and their complexation with mucoadhesives51–56. Here we use the technique of environmental 
scanning electron microscopy (ESEM)57 to visualise the large supramolecular complexes resulting from the inter-
actions of vancomycin with PGM, PIM and BSM under controlled dehydration in the ESEM sample chamber. 
Mucin-vancomycin mixtures, or vancomycin alone or mucin alone controls were observed under an operating 
pressure of ~4 to 5 Torr (Figs. 6–8).
Although the technique of ESEM is useful for the visualisation of a range of sample sizes from ~10 nm to large 
cells and tissues58–60, so far (and to the best of our knowledge) there has been limited application of ESEM for the 
study of antibiotic complexation. In our study, the samples were analysed under the same chemical conditions as 
previously used for the AUC and DLS experiments described above, with samples (prior to drying) in 0.1 M PBS. 
The conditions employed resulted in the formation of salt crystals interspersed between the molecules.
For the PGM system, at a constant magnification (Fig. 6a–c), few (if any) visible particles were evident for the 
vancomycin-only control, apart from the small air bubbles formed during drying (Fig. 6a). The PGM mucin-only 
control sample showed formation of well-separated smooth elongated structures ( < 1 µm) (Fig. 6b). By contrast, 
the mucin-vancomycin mixture showed very large aggregates (Fig. 6c), consistent with our hydrodynamic analysis. 
Closer examination of these aggregates showed that they were composed of spherical grains (~0.2 µm) that were 
not observed in either of the controls, and which appeared to clump together to form the large aggregate struc-
tures shown (Fig. 6d). Very similar behaviour was seen for the PIM system with large aggregation in the presence 
of vancomycin but nothing in the absence apart from salt crystals (Fig. 7). Similar behaviour was also seen for the 
bovine submaxillary mucin although complexes were generally smaller (Fig. 8).
Therefore, the ESEM analysis undertaken here appears to reinforce the hydrodynamic data that vancomycin 
induces mucin aggregation. The exact mechanism is currently under investigation but electrostatic binding of the 
charged amino groups (possessing an overall positive charge of ~+0.67 at neutral pH) present on the vancomycin 
to the sialic acid residues present in the mucin may at least be a contributory factor. i.e. this may involve “bridging” 
electrostatic forces as have been well described for other systems61–64. It is worth noting that in the stomach the 
pH (1.5–3.5) is ~ the pKa of sialic acid (2.5), whereas the pH of the intestine is ~ 6.0–7.4 and that of the mouth 
~7.5. The effect of pH on the interactions and also the influence of bile salts – with the appropriate vancomycin 
and mucin controls (see, for example refs. 65,66) would be a fruitful source of further investigation.
Figure 5. Distribution of z-average apparent hydrodynamic diameters, dz,app from dynamic light scattering 
measurements on mucin and vancomycin at differing mixing ratios (a) 0.5 mg/mL PGM + 0.125 mg/mL (blue 
line), +1.25 mg/mL (dark green), +12.5 mg/mL (red). The 0.5 mg/mL PGM control is shown in black. (b) 
0.5 mg/mL PIM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark green), +12.5 mg/mL (red). The 0.5 mg/mL 
PIM control is shown in black and (c) 1.0 mg/mL BSM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark green), 
+12.5 mg/mL (red). The 1.0 mg/mL BSM control is shown in black. Because free vancomycin scatters too 
weakly at the concentrations in the mixtures, for the vancomycin control (purple) a higher concentration of 
50 mg/mL was used.
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Discussion
If we make the assumption that our observations for model mucin systems – based on the commonly used pig 
mucin model - can be extended to human mucin systems, vancomycin-mucin interactions may provide one 
explanation for the well documented poor absorption characteristics of orally-administered vancomycin13,27. The 
large mucin glycoproteins, together with salts, lipids and other proteins that make up mucus, provide a strong 
selective barrier for passage of only low molecular weight components such as mono-, di- or tri-peptides67,68 and 
hydrophilic, net neutral charge particles that can permeate the mucin mesh size of ~100 nm69,70; monomeric 
vancomycin is a large glycopeptide with a molar mass of ~1500 Da.
The poor absorption of vancomycin is presumably attributable in part to its relatively larger mass and also 
its overall positive charge at71 pH < ~8.5 which prevents it from penetrating the mucus layer by binding and 
aggregation events. Our current findings indicate that the binding of vancomycin to mucin itself would provide 
an additional and effective mechanism for its exclusion from intestinal and gastric absorption when the antibiotic 
is administered orally. It seems possible to conclude from our studies that mucin binding by vancomycin occurs 
whether it is in mainly dimeric or monomeric forms, as suggested by the consistent binding observed when the 
antibiotic is mainly monomeric (at 0.125 mg/mL), approximately 50% dimerized (at 1.25 mg/mL, the typical stool 
concentration) and at the higher 12.5 mg/mL at which the antibiotic is mostly dimeric4, though further studies 
are required to verify this.
However, it should also be borne in mind that, for most glycopeptide antibiotics studied to date72–74 including 
vancomycin66, it has been shown that binding to depsipeptide targets is accompanied by formation of asymmet-
ric, back-to-back homodimers of the glycopeptide in aqueous solution and that this is mediated by sugar-sugar 
recognition75,76. Although glycopeptide antibiotics are known to bind or interact with protein targets such as 
d-alanyl-d-alanine and VanS4,6, precipitation with another glycoprotein, heparin, has also been reported previously. 
However, this only appears to occur at relatively high concentrations of both components such as those used in 
intravenous lines (vancomycin at 1–5 mg/mL and heparin at 1–1000 Units/mL)77–80.
Administration of vancomycin, whether orally or intravenously, has been reported to result in development 
of vancomycin-resistant enterococci (VRE) populations29,30. However, it is the oral administration that appears to 
be the most strongly associated with increased risk of VRE infection or colonization30–33. Although the emergence 
of VRE as nosocomial pathogens is thought to occur from VRE reservoirs built up in the antibiotic-perturbed 
GI tract following ingestion from the hospital environment81,82, it is also possible that some contribution to the 
emergence of VRE populations (including in healthy, community-based individuals who carry low-level VRE) 
may be made by the possible prolonged period of time that vancomycin remains in the GI tract resulting from 
mucin binding, assuming that aggregates are not rapidly cleared from the GI tract and that the antibiotic remains 
exposed within the aggregated state.
Figure 6. Environmental scanning electron micrographs of vancomycin (a), pig gastric mucins (b) and the 
complexes resulted from their interaction (c,d) suspended in 0.1 M PBS (pH 7.0). Aqueous samples were subjected 
to dehydration in the ESEM sample chamber at operating pressures ranging from ~4 to ~5 Torr. Small globular 
grains forming the supramolecular aggregate as shown in panel (d), a magnification of lower left panel (c).
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Mucin binding to vancomycin may provide increased exposure for target pathogens and for resident 
mucin-bound enterococci and other microorganisms to the antibiotic, resulting in increased activation of resist-
ance and selection for VRE populations. If confirmed, this finding may be of significance not only for oral admin-
istration strategies but also for adjunctive intracolonic vancomycin (ICV) therapy strategies which are also used 
to treat pseudomembranous colitis83.
To conclude, there is evidence of strong complexation between vancomycin and model mucins from different 
parts of the GI tract, as shown by analytical ultracentrifugation (Figs. 2–4), DLS (Fig. 5) and further confirmed 
by ESEM (Figs. 6–8). The strongest interactions - with very large complexes being formed (Figs. 2 and 3) - appear 
to be associated with mucus originating from the stomach and small intestine, compared with the mouth. The 
lower degree of association of the latter (Fig. 4, Table 1) may be connected with the lower degree of glycosyla-
tion of submaxillary mucins. Our study suggests that vancomycin may interact with the carbohydrate region of 
mucins, although interactions with the protein component of mucins cannot be excluded. In that regard it would 
be interesting to explore further the role of the glycosylation of mucins and to O-deglycosylate the proteins (or 
find sources of non-glycosylated recombinant mucins) and perform similar studies with vancomycin – provided 
the deglycosylated mucins are sufficiently soluble.
Finally it should be stressed that although pig gastrointestinal mucins are considered a good model for human 
mucins the extension of our conclusions to the case for humans is still only provisional. Nonetheless our demon-
stration - for the first time - of complexation/depletion interactions for model mucin systems with vancomycin 
provides the basis for further study on how orally administered vancomycin might relate to glycopeptide transit 
in humans67.
Methods
Vancomycin. Vancomycin hydrochloride was obtained from Sigma-Aldrich, United Kingdom. A partial 
specific volume ῡ of 0.67 mL g−1 was used4,84. Solution concentrations of vancomycin c (g/mL) were determined 
densimetrically from the relation:
ρ ρ υρ= − −c ( )/(1 ) (1)o o
where ρ and ρo are the solution and solvent densities respectively, measured on an Anton-Paar (Graz, Austria) 
digital density meter. This is simply a re-arrangement of the well-established relation85 of Kratky and co-workers 
for the partial specific volume measured at a single solute concentration.
Figure 7. Environmental scanning electron micrographs of vancomycin (a), pig intestinal mucins (b) and the 
complexes resulted from their interaction with vancomycin (c,d) suspended in 0.1 M PBS (pH 7.0). Aqueous 
samples were subjected to dehydration in the ESEM sample chamber at operating pressures ranging from ~4 to 
~5 Torr. Small globular grains forming the supramolecular aggregate as shown in panel (d), a magnification of 
lower left panel (c).
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Pig gastric mucin, PGM. A 5 mg/mL stock solution of pig gastric mucin was prepared by dissolving 50 mg 
of porcine stomach mucin (Sigma-Aldrich, catalogue no. M1778, type III) in 10 mL of phosphate-buffered saline 
(PBS) buffer, pH 7.0, adjusted to an ionic strength I = 0.1 M by the addition of NaCl (Life Technologies Australia 
Pty Ltd., Invitrogen division, catalogue no. 14190250) according to Green86.
Pig intestinal mucin, PIM. This was prepared as described previously87. Fresh porcine small intestine 
obtained from a local slaughterhouse was rinsed with 67 mM phosphate buffer (pH 6.7) containing 0.02% w/v 
sodium azide and a mix of protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany; 1 tablet per 
50 mL buffer) to remove debris. Mucus was removed by a gentle scraping of the epithelial surface of the jejunum 
segment of the intestine with a plastic scraper (Corning, NY, USA). Extraneous debris (such as dead epithelial 
cells) was removed by extracting the mucus overnight at 18–22 °C with gentle (30 rpm) stirring in 7 volumes of 
extraction buffer (10 mM sodium phosphate, pH 6.5, containing 4 M guanidine hydrochloride, 5 mM EDTA, 5 
mM N-ethylmaleimide and 0.02% w/v sodium azide). Precipitated material was collected by centrifugation for 
30 min at 22000 × g (10.0 °C) and re-extracted in the same way with 10 volumes of extraction buffer, followed by 
centrifugation for 30 min at 22000 × g (10 °C). The insoluble precipitate (crude mucin) was collected and stored 
at −80 °C. The crude mucin was diluted with 10 mM sodium phosphate buffer (pH 6.5) containing 6 M guanidine 
hydrochloride and adjusted to a density of 1.4 g/mL with CsCl and centrifuged (55000 rpm at 10.0 °C for 62 h).
Aliquots of 0.5 mL were sampled, the absorption at 280 nm was measured, and 2 μL of each fraction was spot-
ted and stained with Alcian blue. UV- and Alcian blue-positive aliquots were pooled and diluted in extraction 
buffer lacking guanidine hydrochloride (final guanidine hydrochloride concentration 0.5 M), adjusted in density 
to 1.41 g/mL with CsCl and centrifuged again (50000 rpm at 10.0 °C for 96 h). One-millilitre aliquots were sam-
pled, measured at 280 nm and stained with Alcian blue. The fraction at densities of 1.55–1.60 g/mL was strongly 
Alcian blue-positive and had very weak absorption at 280 nm, identifying it as the mucin fraction. This fraction 
was then dialysed against phosphate-buffered saline (PBS; 10000 g/mol cut-off tubing) and stored at 4 °C before 
use. All solutions were made up in PBS to a final ionic strength of 0.1 M and pH 7.0 to a stock concentration of 
~0.7 mg/mL.
Bovine submaxillary mucin, BSM. A 5 mg/mL stock solution was prepared by dissolving 50 mg of BSM 
(Sigma-Aldrich, catalog no. M3895, type I-S) in 10 ml of phosphate-buffered saline (PBS) buffer, pH7.0, adjusted 
to an ionic strength I = 0.1 M as described previously86.
Figure 8. Environmental scanning electron micrographs of vancomycin (a), bovine submaxillary mucins 
(b) and the complexes resulted from the interaction with vancomycin (c,d) suspended in 0.1 M PBS (pH 7.0). 
Aqueous samples were subjected to dehydration in the ESEM sample chamber at operating pressures ranging 
from ~4 to ~5 Torr. Small globular grains forming the supramolecular aggregate as shown in panel (d), a 
magnification of lower left panel (c).
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Sedimentation velocity in the Analytical Ultracentrifuge (AUC). Experiments were performed at 
20.0 °C using the Optima XL-I analytical ultracentrifuge (Beckman, Palo Alto, USA) equipped with Rayleigh 
interference optics, as described previously88. Sample volumes of 395 μl (or 405 μl for reference solvent), were 
injected into the 12 mm double sector epoxy cells with sapphire windows and run at 45000 rpm. Scans were 
taken at 2 minute intervals. The interference system produced data derived by recording changes in concen-
tration (in fringe units) versus radial displacement. The data was analysed in SEDFIT using the least squares, 
ls-g*(s) processing method - g(s) by generating sedimentation coefficient distributions, s20,w (in Svedberg units, 
S = 10−13sec) normalised to standard conditions (viscosity, density of solvent at 20.0 °C)4,6. The following mix-
ing ratios were used (Figs. 2–3): 0.5 mg/mL mucin + 0.125 mg/mL vancomycin (blue line), +1.25 mg/mL (dark 
green), +12.5 mg/mL (red) vancomycin. The 0.5 mg/mL mucin controls are shown in black. For BSM, (Fig. 4) we 
used a higher concentration of ~1 mg/mL to compensate for its lower molecular weight and lower non-ideality 
for a given concentration.
Dynamic light scattering. Dynamic or quasi-elastic light scattering (DLS or QLS) measurements were 
made on the fixed scattering angle Zetasizer Nano-S system (Malvern Instruments Ltd., Malvern, UK)50,89, 
equipped with a 4 mW He-Ne laser at a wavelength of 632.8 nm. Samples in solution were measured in a quartz 
cuvette at 20.0 °C. A scattering angle of 173° was used, and collected in manual mode, requiring a measure-
ment duration of 90 seconds. The resulting data were analysed using the “DTS (Version 4.2)” software (Malvern 
Instruments Ltd., Malvern, UK), providing a volume distribution of translational diffusion coefficients based on 
the CONTIN program of Provencher (1992)48. The volume distribution was followed49. The viscosity of the buffer 
used was calculated using a solvent builder interface and takes the effects of buffer salts into account.
The apparent z-average apparent hydrodynamic diameters dz,app (nm), were evaluated from the z-average 
apparent translational diffusion coefficients Dz,trans,app = by the Stokes-Einstein equation (see e.g., Harding et al.)89:
piη= { }d k T D/ 3 (2)z app B z trans app, , ,
where kB is the Boltzmann constant, T is absolute temperature and η is the viscosity of the medium. The following 
assumptions were made (i) the solutions were sufficiently dilute that non-ideality effects were not significant – i.e. 
an extrapolation to zero concentration was not necessary. This is reasonable as the non-ideality due to the low 
concentration of mucin and small size of vancomycin, and also for translational diffusion the two main contribu-
tory factors to non-ideality – the hydrodynamic and thermodynamic terms - compensate for each other and can 
even cancel each other out90,91. (ii) the particles (vancomycin, mucin and complex) were quasi-spheroidal and not 
asymmetric so there was no angular dependence of the measured Dz,trans values on anisotropic rotational diffusion 
effects – i.e. an extrapolation to zero angle was not necessary92.
The following mixing ratios were used (Fig. 5): (a) 0.5 mg/mL PGM + 0.125 mg/mL vancomycin (blue line), 
+1.25 mg/mL (dark green), +12.5 mg/mL (red). The 0.5 mg/mL PGM control is shown in black. (b) 0.5 mg/mL 
PIM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark green), +12.5 mg/mL (red). The 0.5 mg/mL PIM control is 
shown in black and (c) 1.0 mg/mL BSM + 0.125 mg/mL (blue line), +1.25 mg/mL (dark green), +12.5 mg/mL 
(red). The 1.0 mg/mL BSM control is shown in black. Because free vancomycin scatters too weakly at the con-
centrations in the mixtures, for the vancomycin control (purple) a higher concentration of 50 mg/mL was used.
Environmental Scanning Electron Microscopy (ESEM) analysis. Vancomycin and mucin samples 
were analysed using a Thermofisher Scientific (Waltham, USA) FEI Quanta 650 ESEM. Samples were cooled to 
2.0 °C by means of a Peltier cooling stage, and the pressure of water vapour in the chamber was adjusted to main-
tain a relative humidity of between 80 to 90%, or for the mucin control between 50 to 60%. An accelerating volt-
age of 15 kV was used for all samples. The following mixing ratios were used: 0.5 mg/mL mucin control, 12.5 mg/
mL vancomycin control and 0.5 mg/mL + 12.5 mg/mL mixture.
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